$ News

Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right

Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

Allogene's Q1 Earnings In Line With Estimates, Sales Nil

Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

GSK prepares to relaunch Blenrep; Activists challenge another ‘zombie’ biotech

Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

Elevation Oncology Plunges 42% on Ending Development of Lead Drug

Elevation Oncology downgraded as it halts lead asset on disappointing trials

Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options

Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements

Elevation Oncology to Participate in Upcoming Investor Conferences

Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones

Why Elevation Oncology (ELEV) Is Among the Best Penny Stocks to Invest In According to Media?

Bipartisan lawmakers appear 'aligned' on PBM, insurance reform

Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors

Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024

Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference

Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements

What Makes Elevation Oncology (ELEV) a New Strong Buy Stock

Empery Asset Management's Strategic Acquisition in Elevation Oncology